Dashboard Tools Market News Investing Ideas Pricing
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in

Nephrocare Health Services Ltd
NSE:NEPHROPLUS

Watchlist Manager
Nephrocare Health Services Ltd Logo
Nephrocare Health Services Ltd
NSE:NEPHROPLUS
Watchlist
Price: 694.65 INR -0.29% Market Closed
Market Cap: ₹69.9B
Write Note Create Alert Ask AI

Wall St Price Targets

NEPHROPLUS Price Targets Summary
Nephrocare Health Services Ltd

Wall Street analysts forecast NEPHROPLUS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NEPHROPLUS is 795.6 INR with a low forecast of 666.6 INR and a high forecast of 1 050 INR.

NEPHROPLUS Lowest Forecast
Wall Street Target
₹666.6
-4% Downside
NEPHROPLUS Average Forecast
Wall Street Target
₹795.6
15% Upside
NEPHROPLUS Highest Forecast
Wall Street Target
₹1 050
51% Upside
Lowest Forecast
Price Target
666.6 INR
4% Downside
Average Forecast
Price Target
795.6 INR
15% Upside
Highest Forecast
Price Target
1 050 INR
51% Upside
Nephrocare Health Services Ltd Competitors:
Price Targets
OGI
OrganiGram Holdings Inc
78% Upside
ALG
Alamo Group Inc
31% Upside
OGI
OrganiGram Holdings Inc
78% Upside
ALG
Alamo Group Inc
31% Upside

Revenue
Forecast

33% / Year
Past Growth
15% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
33% / Year
Past Growth
15% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 2 years, the compound annual growth rate for Revenue has been 33%. The projected CAGR for the next 7 years is 15%.

What are analyst estimates?

Gross Profit
Forecast

42% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
42% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Gross Profit Forecast
is not available for Nephrocare Health Services Ltd

Operating Income
Forecast

67% / Year
Past Growth
16% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
67% / Year
Past Growth
16% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 2 years, the compound annual growth rate for Operating Income has been 67%. The projected CAGR for the next 7 years is 16%.

What are analyst estimates?

Pre-Tax Income
Forecast

71% / Year
Past Growth
75% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
71% / Year
Past Growth
75% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 2 years, the compound annual growth rate for Pre-Tax Income has been 71%. The projected CAGR for the next 2 years is 75%.

What are analyst estimates?

Net Income
Forecast

48% / Year
Past Growth
48% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
48% / Year
Past Growth
48% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 2 years, the compound annual growth rate for Net Income has been 48%. The projected CAGR for the next 3 years is 48%.

What are analyst estimates?

Continue NEPHROPLUS Research

Summary
NEPHROPLUS intrinsic value, competitors valuation, and company profile.
DCF Valuation
NEPHROPLUS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NEPHROPLUS stock valuation using valuation multiples.
Wall St Estimates
NEPHROPLUS price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NEPHROPLUS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is NEPHROPLUS's stock price target?
Price Target
795.6 INR

According to Wall Street analysts, the average 1-year price target for NEPHROPLUS is 795.6 INR with a low forecast of 666.6 INR and a high forecast of 1 050 INR.

What is the Revenue forecast for Nephrocare Health Services Ltd?
Projected CAGR
15%

Over the last 2 years, the compound annual growth rate for Revenue has been 33%. The projected CAGR for the next 7 years is 15%.

What is the Operating Income forecast for Nephrocare Health Services Ltd?
Projected CAGR
16%

Over the last 2 years, the compound annual growth rate for Operating Income has been 67%. The projected CAGR for the next 7 years is 16%.

What is the Pre-Tax Income forecast for Nephrocare Health Services Ltd?
Projected CAGR
75%

Over the last 2 years, the compound annual growth rate for Pre-Tax Income has been 71%. The projected CAGR for the next 2 years is 75%.

What is the Net Income forecast for Nephrocare Health Services Ltd?
Projected CAGR
48%

Over the last 2 years, the compound annual growth rate for Net Income has been 48%. The projected CAGR for the next 3 years is 48%.

Back to Top
ALPHA SPREAD
Follow us
Join 353,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett